According to filings with the U.S. Securities and Exchange Commission, Intellistem is raising up to $5,000,000.00 in new funding. Sources indicate that as part of senior management President, William StJohn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Intellistem
IntelliStem introduces groundbreaking technology to the Cell Vaccine Industry. Intellistem, Inc. is a clinical-stage biotech that develops innovative cellular immune cancer therapy approaches. The Company has demonstrated the therapeutic potential and safety of its’ Super Sentinel Gamma Delta Cell (SCC) Platform in Human Studies. We are committed to increasing patient access to cell therapy by offering safer, less costly approaches for treating solid and liquid cancers. Intellistem’s SSC Cells represent a potentially attractive alternative to costly patient-derived CAR-T Cells used to treat blood cancers. SSC cells are ideal for cell therapy due to their broad antigen recognition, ability to treat solid tumors. SSC cells are produced as an allogeneic cell-based off-the-shelf pharmaceutical.

To learn more about Intellistem, visit http://www.intellistemtech.com/
Intellistem Linkedin Page: https://www.linkedin.com/company/intellistem-technologies-inc/

Contact:
William StJohn, President
415-547-9066
https://www.linkedin.com/in/bill-st-john-13252b1a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.